| Epigenetic modification of m6A regulator proteins in cancer Y Wang, Y Wang, H Patel, J Chen, J Wang, ZS Chen, H Wang Molecular Cancer 22 (1), 102, 2023 | 69 | 2023 |
| Drug resistance: from bacteria to cancer H Patel, ZX Wu, Y Chen, L Bo, ZS Chen Molecular Biomedicine 2, 1-19, 2021 | 29 | 2021 |
| Establishment and characterization of an irinotecan-resistant human colon cancer cell line ZX Wu, Y Yang, L Zeng, H Patel, L Bo, L Lin, ZS Chen Frontiers in oncology 10, 624954, 2021 | 27 | 2021 |
| Palmitoyl carnitine-anchored nanoliposomes for neovasculature-specific delivery of gemcitabine elaidate to treat pancreatic cancer A Patel, A Saraswat, H Patel, ZS Chen, K Patel Cancers 15 (1), 182, 2022 | 13 | 2022 |
| Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy LQ Cao, H Sun, Y Xie, H Patel, L Bo, H Lin, ZS Chen Frontiers in Pharmacology 15, 1340764, 2024 | 10 | 2024 |
| Nanotechnology-based delivery systems to overcome drug resistance in cancer H Patel, J Li, L Bo, R Mehta, CR Ashby Jr, S Wang, W Cai, ZS Chen Medical Review 4 (1), 5-30, 2024 | 4 | 2024 |
| Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer S Shukla, H Patel, S Chen, R Sun, L Wei, ZS Chen Cancer Pathogenesis and Therapy 2 (03), 135-141, 2024 | 1 | 2024 |
| ABCB1-mediated chemotherapeutic drug resistance is reversed by a potent p53-MDM2 inhibitor NVP-HDM201 H Patel, C Cai, Z Wu, Q Teng, H Li, ZS Chen Cancer Research 84 (6_Supplement), 7193-7193, 2024 | | 2024 |
Zhe-Sheng ChenCollege of Pharmacy and Health Sciences, St. John's UniversityПодтвержден адрес электронной почты в домене stjohns.edu